Introduction {#Sec1}
============

Traumatic brain injury (TBI) patients are prone to develop fatal complications because of their primary pathology and are at risk of secondary complications such as aspiration pneumonitis, ventilator-associated pneumonia (VAP), and sepsis. Prompt diagnosis and management are necessary to reduce morbidity and mortality \[[@CR1]\]. In normal and healthy individuals, procalcitonin (PCT) is produced in thyroid cells. Calcitonin when activated is involved in calcium and phosphorus homeostasis. Virtually all PCT is converted to calcitonin in healthy subjects so that the circulating level of PCT is \< 0.05 ng/ml. With inflammation, PCT is produced by a direct lipopolysaccharide (or other toxic metabolite from microbes) pathway and an indirect pathway from inflammatory mediators \[[@CR2]\]. This has been demonstrated in previous studies that PCT levels are found to be raised in patients with bacterial sepsis, systemic inflammatory response syndrome (SIRS), and also after traumatic injury therefore can aid in prompt diagnosis \[[@CR3]--[@CR6]\]. PCT levels may be a better indicator in the early diagnosis of septic complications in patients with multiple trauma \[[@CR3]\]. However, during the first 2 days after trauma elevated PCT levels are more likely to be indicative of traumatic origin than of an ongoing sepsis, and multiple events such as surgery, massive transfusion, intensive care therapy might influence the PCT concentration \[[@CR7]\]. TBI is associated with the majority of trauma deaths \[[@CR8]\]. Clinicians are often confronted with questions related to the severity of injury and prognosis. Predicting outcome becomes difficult due to the heterogeneity of TBI, some patients recover well, while others are left with severe neurological disability. Objective tools are required to understand the severity of injury and then these tools can be useful to predict the prognosis. The application of a biomarker like PCT for TBI could lead to assess the severity and thus help in prognostication and correlation with mortality and outcome. We hypothesize that greater severity of TBI and/or associated extracranial injuries is more often encountered with higher PCT concentration and poor outcomes.

PCT has been seen as the prognostic marker in multiple traumatic injury patients, but its comparative role has not been assessed as a prognostic marker based on outcomes in different types of TBI \[[@CR3]--[@CR6]\]. This study was planned to determine outcome in different groups of TBI patients with and without extracranial injury as assessed by serial evaluation of PCT.

Objectives {#Sec2}
==========

Primary objective is to determine the correlation between PCT concentrations with TBI outcomes (primarily, in-hospital mortality) at neurointensive care unit (ICU)/hospital discharge assessed using Glasgow outcome scale (GOS). The secondary objectives are to evaluate for any correlation with associated extra cranial injuries and complications during hospital stay.

Materials and Methods {#Sec3}
=====================

After approval from institutional ethics committee (ref. no. IEC/NP-391/2012 & RP-43/2012), all patients with TBI admitted to the ICU at the level 1 apex trauma center unit were prospectively included in the study. This study has been registered prospectively with clinical trial registry of India (CTRI/05/008466). The patients were divided into two major groups: head injury with extracranial injury or without extracranial injury. The inclusion criteria were patients with head injury aged \> 18 years, and survival for at least 12 h after admission admitted to the study center within 8 h of injury and patients with positive head injury findings on computer tomography (CT) scan. Exclusion criteria included patients with pre-existing sepsis or with chronic kidney disease on regular dialysis requirement, patients with history of drug abuse or any anaphylaxis. Patients were treated according to the institutional protocol and accepted standards of care. PCT, all laboratory, microbiological, and clinical data with duration of treatment in the ICU/hospital were noted. PCT values were obtained on day 1, 2, and 5 after trauma. The PCT levels were measured by the mini VIDAS^®^ assay, Biomerieux Pvt. Ltd., i.e., based on the enzyme-linked fluorescent assay principal. The PCT level more than 0.5 ng/ml was taken as positive and greater than 10 ng/ml as highly significant. The data collected during admission were age, gender, mode of injury (road traffic accident, fall, or assault), chronic conditions if any, GCS, severity of trauma according to ISS (injury severity score) \[[@CR9]\], and number of blood units transfused within first 24 h after trauma. Complications included were suspected pneumonia, SIRS, sepsis, or septic shock and the occurrence of organ dysfunction (respiratory, cardiac, renal, or hepatic). The amount of blood loss was also noted. The final data analyzed were survival data at discharge from the ICU and hospital. Intravenous (IV) broad spectrum antibiotics were administered to all ICU-admitted patients in accordance with ICU and hospital protocol.

Brain CT scans of TBI patients were rated by using the Marshall grading scale \[[@CR10]\]. After primary diagnostic assessment and/or surgery, all patients were transferred to the ICU and received standard intensive care, including intubation and mechanical ventilation, hemodynamic and intracranial pressure (ICP) monitoring using Codman microsensor™ based on the severity of injury and institutional protocol. Lastly, 1 month after the primary injury, the study protocol was documented for outcome according to the survival and GOS scoring 1--5 (1, dead; 2, persistent vegetative state; 3, severely disabled; 4, moderately disabled; 5, good recovery). The probable etiology of mortality was also noted. The primary mortality was defined as loss of life because of severity of trauma-induced CNS pathology in TBI patients, whereas secondary mortality as mortality because of complications in TBI patients such as sepsis, VAP, coagulopathy, or associated injuries. Final outcome on discharge was classified on basis of GOS as good outcome (scoring 4--5) or poor outcome (score of 2--3).

Statistical Analysis {#Sec4}
--------------------

Nonparametric continuous variables are expressed as the median and inter-quartile ranges, and normally distributed variables are presented as the mean ± standard deviation (SD). Statistical data were analyzed using Stata Corp. 2015. Stata Statistical Software: (Release 14) College Station, Texas. PCT levels among TBI patients with and without extracranial injuries groups were carried out using Kruskal--Wallis tests (data not normally distributed), and if statistical significance of differences was detected, then the two-sample Wilcoxon rank-sum (Mann--Whitney) (nonparametric analysis) was used for further comparisons between the two comparison groups. We used the Pearson Chi-square test (χ2 test) and Fisher's exact test to compare proportions. Univariate and multivariate logistic regression with odds ratio was used to assess the performance of the variables in the prediction of primary or secondary outcome. The sample of the present study was a result of the inclusion of patients admitted to ICU of a level 1 trauma center in a 2-year period. Thus, a post hoc analysis was performed to determine the power of the study calculated out to be nearly 80% for the primary outcome.

Results {#Sec5}
=======

A total of 188 patients were screened for this study out of those 2 were excluded (1 refused consent and other did not meet criteria for inclusion) in accordance with STROBE flow chart of patient's recruitment (Fig. [1](#Fig1){ref-type="fig"}). Hence, 186 patients were included in the study between January 2014 and January 2016 for the first wave of data collection followed by 163 patients for the second wave and finally 110 for the last wave of data collection (Fig. [1](#Fig1){ref-type="fig"}). Table [1](#Tab1){ref-type="table"} compares the baseline demographic and various clinical characteristics between patients. The majority of patients presented were found to have intracranial pathologies like subdural hematoma (SDH), extradural hematoma (EDH), contusions, subarachnoid hemorrhage (SAH), intraventricular hemorrhage (IVH), and diffuse axonal injuries (DAI) (Table [2](#Tab2){ref-type="table"}). Twenty-eight TBI patients were found to have associated extracranial injuries or positive FAST (Focused Assessment Sonography in Trauma) scan findings. The median PCT levels in severe TBI patients with GCS \[[@CR3]--[@CR5]\] were found to be consistently higher (3.37 on day 1, 2.1 on day 2, and 1.25 on day 5) at all time than patients with GCS in range 6--8; or 9--12 (Table [3](#Tab3){ref-type="table"}). Among them, long bones (femur/radius/ulna/tibia/fibula) or pelvis fractures were noted in 14 patients, maxillo-facial fractures in 11 patients, lung contusions (unilateral/bilateral) in 10 patients, C~1~--C~2~ spine subluxation in 6 patients, splenic tear/laceration in 8 patients, liver contusions/lacerations in 7 patients, hemo-pneumothorax in 5 patients, bilateral/unilateral lung contusions in 4 patients, and intestinal tear/laceration in 3 patients. We were able to get ICP monitoring in only 17 patients (out of total 21 DAI patients). In rest other cases/indications, serial clinical CNS examinations (decreased GCS/power/abnormal pupil size/reactivity) and regular hemodynamic monitoring (sudden perturbance in HR, BP) were the tip to proceed with decompressive craniectomy. Thirty-seven patients (22.7%) among the 163 studied patients met with sepsis/bacteremia at any point of hospital or ICU stay; 20 patients died among them from other than primary CNS cause of mortality, among them, 2 died from VAP or acute respiratory distress syndrome (ARDS) and 1 patient from septic shock. The median PCT levels were 2.49 (range 0.05, 59.1) and 3.36 (range 0.06, 24.1) ng/ml on day 2 and 5, respectively, among septic TBI patients, i.e., found to be highly significant compared to PCT in other TBI patients (Table [4](#Tab4){ref-type="table"}). Among all factors observed, only presence of SDH, presence of dilated pupils, coagulopathy, hemodynamic instability, and poor GCS at admission were found to have statistically significant association with primary mortality (*p *\< 0.05) (Table [1](#Tab1){ref-type="table"}). In this study, median PCT level at admission, day 2, and day 5 in TBI patients with extracranial injuries was 3.0, 0.83, and 0.69 ng/ml. However, this was statistically found to be comparable with TBI patients without any extracranial injuries (Table [5](#Tab5){ref-type="table"}). Considering PCT as a prediction marker of survivor or nonsurvivor, we observed median values at admission (13.09 ng/ml) and on day 2 (6.37 ng/ml) were significantly very high (*p* ≤ 0.001) in TBI patients those who succumbs later (Table [6](#Tab6){ref-type="table"}). We did not observe any significant association of parameters like length of ICU stay, GOS, and secondary mortality with the presence of extracranial injuries in TBI patients as compared to those with TBI alone (*p* value \> 0.1; Table [7](#Tab7){ref-type="table"}). Furthermore, through receiver operating curve (ROC) curve analysis we found that PCT levels at day 1 had a highest discriminating ability for primary mortality (AUC 78% and cutoff level more than 5.5 ng/ml carried maximum sensitivity and specificity of 75%) followed by PCT levels on day 2 with discriminating ability for secondary (sepsis, etc.) mortality (cutoff values more than 1.15 ng/ml had sensitivity of 70% with specificity of 66%) (Table [8](#Tab8){ref-type="table"}). Further we found that there was no significant difference in PCT levels at day 5. On univariate analysis, PCT (on day 1and 2) cutoff values more than 5.5 ng/ml and 1.16 ng/ml had odds ratio \[OR\] of 9.1 and 4.2, respectively, for primary mortality. After adjusting for other known confounders like age, comorbidities, or infection at admission and complications (viz post-injury sepsis, VAP, associated injuries, FAST-positive status, positive X-ray findings for aspiration pneumonitis/pneumothorax/hemothorax/pleural-effusion/atelectasis, and coagulopathy) the adjusted OR was 8.2 and 6.3 on day 1 and 2, respectively. Similarly, for secondary mortality and final outcome at discharge from hospital, PCT cutoff values at admission (\> 2.07 ng/ml), on day 2 (\> 1.15 ng/ml) presented with OR (3.4; 3.6) and (3.43; 4.9), respectively, and after adjusting for confounding factors like primary mortality, mechanism of trauma, intracranial HTN, presence of intracranial CT findings, dilated pupils, and perioperative factors (decompressive craniectomy, blood loss, duration of surgery, blood product transfusion, colloid administration) adjusted OR were (2.5; 4.8) & (2.9; 4.0), respectively (Table [9](#Tab9){ref-type="table"}). Furthermore, we observed that presence of significant nonoperated EDH, persistent hypoxia before admission was independent risk factors for poor and fatal outcome, while intracranial hypertension and/or hypoxia was independent risk factors for prolonged ICU and hospital stay (Table [1](#Tab1){ref-type="table"}).Fig. 1STROBE flow diagram for recruitment of cases in the studyTable 1Baseline demographics, clinical characteristics of TBI patients in association with primary mortalityAssociation with variablesPrimary mortality*p* valueNo (survivors) freq. (%) \[*n*~1~ = 168\]Yes (died) freq. (%) \[*n*~2~ = 18\]Age (years) \[Mean ± SD\]29.78 ± 5.3232.42 ± 5.920.06Body weight (kgs) \[Mean ± SD\]57.72 ± 16.459.93 ± 15.110.10Gender Female25 (14.7)3 (18.7) Male145 (85.3)13 (81.3)0.712Mechanism of injury Unknown3 (1.7)0 (0) Road traffic accidents117 (68.8)14 (87.5) Fall42 (24.7)2 (12.5) Assault8 (4.7)0 (0)0.584Chronic comorbidities Absent154 (95.0)15 (90.9) Present16 (4.9)1 (9.0)0.45Management Conservative74 (45.6)10 (54.5) Surgical intervention88 (54.3)6 (45.4)0.756Hypertension Absent163 (93.1)9 (81.8) Present12 (6.9)2 (18.1)0.148Inotrope(s) requirement No158 (91.9)9 (81.8) Yes13 (8.0)2 (18.1)0.247Intracranial hypertension (ICP \> 20 mmHg) Absent149 (90.9)8 (72.7) Present14 (9.1)3 (27.2)0.068Subdural hematoma (SDH) Absent117 (72.2)4 (36.36) Present45 (86.5)7 (13.46)**0.018**Contusions No97 (59.8)4 (36.3) Yes65 (40.1)7 (63.6)0.204Extradural hematoma (EDH) No137 (84.5)11 (100) Yes25 (15.4)00.369Diffuse axonal injury (DAI) No143 (88.2)9 (81.8) Yes19 (11.7)2 (18.1)0.626Traumatic SAH/IVH No127 (78.4)7 (63.6) Yes35 (21.6)4 (36.3)0.271Chest X-ray finding No148 (91.3)10 (90.9) Yes14 (8.6)1 (9.0)1.0Dyselectrolytemia No153 (94.4)9 (81.8) Yes9 (5.5)2 (18.1)0.148Associated injuries or (FAST +ve) No162 (93.8)9 (81.8) Yes13 (6.17)2 (18.1)0.17Dilated pupils (unilateral or bilateral) No147 (90.7)4 (36.3) Yes15 (9.2)7 (63.6)**0.0001**Surgery: decompressive craniectomy No108 (66.6)8 (72.70) Yes54 (33.3)3 (27.2)1.00Cervical-spine involvement No149 (85.8)10 (90.9) Yes26 (14.2)1 (9.0)1.00Major blood loss (\> 50% of EBV) No146 (90.1)11 (100) Yes16 (9.8)0 (0)0.602Prolonged duration of surgery (\> 6 h) No143 (88.8)11 (100) Yes18 (11.1)0 (0)0.608Blood products transfusion No137 (85.0)9 (81.8) Yes24 (14.9)2 (18.1)0.673Complications: sepsis No128 (79.0)8 (72.7) Yes34 (21.0)3 (27.3)0.704Coagulopathy No159 (98.1)9 (81.8) Yes3 (1.8)2 (18.2)**0.03**Ventilator-associated pneumonia (VAP/ARDS) No142 (87.6)9 (81.8) Yes20 (12.4)2 (18.2)0.634Hypotension or hypoxia at admission No150 (92.6)6 (54.5) Yes12 (7.4)5 (45.5)**\<0.001**Polytrauma (extracranial involvement) No149 (85.1)9 (81.8) Yes26 (14.9)2 (18.2)0.40Glasgow coma scale---at admission 9--1248 (29.6)0 (0) 4--826 (16.0)1 (9.1) 388 (54.3)10 (90.9)**0.04**Injury severity score (ISS) Median (range)23 (19, 26)26 (21, 30)0.17ICU stay duration Median (range) days5 (1, 28)4.5 (2, 16)0.93Statistically significant numbers are given in bold*No*: were patients who survived, while *Yes*: were patients who died*EBV* estimated blood volume, *FAST* Focused Assessment Sonography in Trauma, *ICP* intracranial pressure, *SAH/IVH* subarachnoid or intraventricular hemorrhageTable 2Radiological characteristics of patients with moderate to severe TBI on admissionInitial CT brain findings (in majority of cases)Marshall CT gradingNo. of patients (*n *= 186)Nil/not significant lesionsI0Small frontal hematoma/EDH, SDH, DAI grade (I)II15Traumatic diffuse SAH, cerebral edema, IVH, dot contusions, DAI grade (II--III) \[MLS ≤ 5 mm\]III35Large FTP SDH/contusions (lesions size \< 25 cm^3^ but with MLS \> 5 mm)IV25(lesions size \> 25 cm^3^ with MLS \> 5 mm) Operated/surgically evacuated lesionsV94Diffuse SAH, posterior fossa IC bleed, basifrontal/brainstem contusions, large occipital SDH (or lesions size \> 25 cm^3^ with established brainstem infarct)VI17*DAI* diffuse axonal injury, *EDH* extradural hematoma, *IC* intracranial, *IVH* intraventricular hemorrhage, *MLS* midline shift, *SAH* sub-arachnoid hemorrhage, *SDH* subdural hematomaTable 3Procalcitonin levels in different subsets of TBI patients based on GCSGlasgow coma scale (GCS) scoreProcalcitonin levelsPCT-1PCT-2PCT-53--53.37 (0.17--152.2)2.1 (0.08--73.4)1.25 (0.16--33.54)6--80.79 (0.05--145.7)0.58 (0.04--65.8)1.0 (0.2--50.6)9--120.58 (0.05--70.1)0.43 (0.05--59.5)0.79 (0.1--24.8)PCT-1, PCT-2, PCT-5 are procalcitonin levels expressed as median (range min.--max.) on admission day, 2nd day, and 5th day in hospital, respectivelyTable 4Procalcitonin levels in TBI patients with and without sepsisProcalcitonin levelsSepsis in TBI patientsStatistical significance (*p* value)Absent (*n *= 126)Present (*n *= 37)PCT-2 (ng/ml)0.42 (0.04, 145.7)2.49 (0.05, 59.1)0.0001PCT-5 (ng/ml)0.47 (0.01, 50.6)3.36 (0.06, 24.1)0.0002PCT values expressed as median (min.--max.) ng/mlTable 5Association of PCT rise with or without extracranial injuries in TBI patientsAssociated extracranial injuriesPCT-1 (ng/ml)PCT-2 (ng/ml)PCT-5 (ng/ml)Absent (*n *= 158)0.97 (0.05, 152.1)0.56 (0.04, 145.7)0.83 (0.0, 50.6)Present (*n *= 28)3.0 (0.33, 27.8)0.83 (0.05, 17.2)0.69 (0.14, 7.9)(*p* value)0.190.830.70Values are expressed as median (range min.--max.)*PCT* procalcitoninTable 6PCT as a marker of survivors versus nonsurvivors in all TBI patients (*No*: were patients who survived, while *Yes*: were patients who died)ParameterPrimary mortalityStatistical significance (*p* value)No (survivors) (*n*~1~ = 163)Yes (died) (*n*~2~ = 18)PCT-1 (ng/ml)1.06 (0.05, 152.2)13.09 (0.17, 65.8)**0.006**PCT-2 (ng/ml)0.50 (0.04, 145.7)6.37 (0.05, 73.3)**0.001**PCT-5 (ng/ml)0.79 (0.0, 50.6)1.32 (0.05, 33.5)0.15Statistically significant numbers are given in boldValues are expressed as median (range min.--max.)*PCT* procalcitoninTable 7Baseline demographics, clinical characteristics in TBI patients with and without extracranial injuriesBaseline demographics and clinical characteristicsHead injury without extracranial injuriesHead injury with extracranial injuries*p* valueNo. of patients158 (84.9%)28 (15.1%)Age (years) (Mean ± SD)32.36 ± 14.834.83 ± 16.00.83Body weight (kgs) (Mean ± SD)58.79 ± 15.2060.33 ± 10.700.92Sex (M:F) ratio5:14:10.7Injury severity score (0--75)22 ± 725 ± 90.05ICU Stay, median (range) days5 (1, 28)5.5 (1, 15)0.47GOS (1--5), median (range)3 (1, 5)2 (1, 5)0.06Primary mortality (%)9 (5.7%)9 (32%)\< 0.0001Secondary mortality (%)18 (11.4%)2 (7.1%)0.36*GOS* Glasgow outcome scale, *M/F* male/female ratioTable 8Area under curve (AUC) for the PCT cutoff values and their sensitivity or specificityOutcomePCT cutoff values (ng/ml)AUC (95% C.I.)Sensitivity (%)Specificity (%)LR+LR−Primary mortalityPCT-1 ≥ 5.50.78 (0.66, 0.89)7575.33.030.33PCT-2 ≥ 1.160.69 (0.48, 0.89)63.663.81.750.56Secondary mortalityPCT-1 ≥ 2.070.67 (0.42, 0.71)66.757.61.570.58PCT-2 ≥ 1.150.65 (0.52, 0.81)7065.72.040.45Poor outcome at dischargePCT-5 ≥ 1.190.70 (0.29, 0.83)57.168.31.80.62*AUC* area under curve, *CI* confidence interval, *LR* likelihood ratio, *PCT* procalcitoninTable 9Univariate and multivariate logistic regression analysis adjustment in outcomes among TBI patientsParametersPCT cutoff value (ng/ml)Yes (died)\
No.(frequency %)No (survivors)\
No. (frequency%)Unadjusted odds ratio (95% CI)*p* valueAdjusted odds ratio (95% CI)*p* valuePrimary mortalityPCT-1 \< 5.54 (3%)128 (97%)1**\< 0.001**1**0.003**PCT-1 ≥ 5.512 (22.2%)42 (77.8%)9.14 (2.8, 29.8)8.21 (2.04, 32.9)PCT-2 \< 1.164 (4%)98 (96%)1**0.039**1**0.023**PCT-2 ≥ 1.167 (11.5%)54 (88.5%)4.2 (1.07, 16.48)6.37 (1.28, 31.58)Secondary mortalityPCT-1 \< 2.073 (1.8%)93 (57%)1**0.003**10.21PCT-1 ≥ 2.078 (4.9%)59 (36.2%)3.43 (1.54, 7.65)2.52 (0.58, 11.0)PCT-2 \< 1.157 (4.3%)95 (58.3%)1**0.009**1**0.01**PCT-2 ≥ 1.1513 (8%)48 (29.4%)3.67 (1.37, 9.81)4.79 (1.38, 16.61)PCT-5 \< 1.192 (1.8%)48 (43.6%)10.0810.05PCT-5 ≥ 1.193 (2.7%)47 (42.7%)1.18 (1.2, 3.5)1.82 (1.32, 3.20)Poor outcomePCT-1 \< 2.0711 (11%)59 (59%)1**0.003**10.16PCT-1 ≥ 2.079 (9%)21 (21%)3.43 (1.54, 7.65)2.92 (0.64, 13.30)PCT-2 \< 1.158 (8%)32 (32%)1**\< 0.001**10.09PCT-2 ≥ 1.157 (7%)53 (53%)4.96 (2.0, 12.22)4.04 (0.80, 20.4)Statistically significant numbers are given in bold*No*: were patients those who survived, while *Yes*: were patients who died\[*Primary mortality* adjusted for factors like age, comorbidities, or infection at admission, complications sepsis, VAP, associated injuries, FAST-positive status, positive X-ray findings, coagulation disorders. *Secondary mortality* adjusted for factors like primary mortality, mechanism of trauma, intracranial HTN, presence of SDH, contusions, diffuse DAI, SAH, IVH, dilated pupils, FAST-positive status, decompressive craniectomy performed, and perioperative factors (blood loss, duration of surgery, blood product transfusion, colloid administration). *Final outcome at discharge* adjusted for primary and secondary mortality, age, mechanism of trauma, comorbidities at admission, inotropes requirement, dilated pupils, FAST-positive status, intracranial HTN, associated C-spine injury, and perioperative factors*CI* confidence interval, *PCT* procalcitonin

Discussion {#Sec6}
==========

This observational longitudinal study demonstrates the relation between PCT concentrations with outcome at day 1, day 2, and day 5 post-injury. This study also attempts to verify its correlation with extracranial injury and infectious complications in severe TBI patients.

PCT is an amino acid peptide, i.e., precursor molecule of calcitonin, without any known hormonal activity \[[@CR11]\]. Serum levels of PCT linearly correlate with bacterial infection/sepsis in patients. The PCT biomolecule has been demonstrated and considered as a diagnostic and prognostic marker of bacterial sepsis among critically ill patients with better accuracy if integrated with clinical evaluation \[[@CR12]\]. On the other hand, PCT has been found capable to differentiate sepsis from other inflammatory causes and aids in vindicating antibiotic therapy in community-acquired pneumonia \[[@CR13]\], lower respiratory tract infection \[[@CR14]\], and sepsis or septic shock \[[@CR15]\].

In the present study, patients with raised plasma PCT concentration on admission were variably associated with various complications, including the length of ICU stay and poor or fatal outcome. Additionally, this was evident from the consecutive raised PCT values in TBI patients that signified as a marker for sepsis soon after the decline in initial trauma-induced high PCT level. The PCT had shown to be of significance in TBI patients at admission and on follow-up examination for improving patient care and understanding prognosis quite early. In previous studies \[[@CR16]--[@CR18]\], polytrauma patients have been prone to develop complications such as infections and sepsis. Levels of PCT were reported to be significantly higher in cases with sepsis or septic shock compared with cases who developed SIRS \[[@CR3]\]. In polytrauma (with abdominal injury) patients, PCT was reportedly found to be significantly increased 3.37 ± 0.92; 3.27 ± 0.97 ng/ml during post-injury day 1 and 2, respectively \[[@CR7]\]. Higher PCT concentrations might pose patients susceptible for greater risk of secondary complications like sepsis, VAP/ARDS, or poor or fatal outcome. However, PCT rise varied according to the severity of trauma that did not correlate with results of our study. Unlike other studies, we did not observe statistical significance on clinical parameters like sepsis, ICU stay, GOS, and secondary mortality in TBI patients with extracranial injuries. Moreover, this can be justified on basis of comparable ISS in each group of patients. However, PCT levels in septic TBI patients after admission (on day 2 and 5) were found to be significantly higher than other TBI patients overall in this study.

In our study, following severe TBI with median ISS of 24, 31 of the 186 analyzed patients died within 5 days after trauma. There was a trend of significantly higher PCT levels (≥ 6.37 ng/ml) within first 3 days in nonsurvivors after TBI as compared with those who survived. All patients who died because of secondary etiology (sepsis or related complications) had PCT levels greater than 1.15 ng/ml at all times. However, polytrauma patients with lung injury were found to have relatively higher PCT levels than rest of multiple injured patients, though found to be statistically insignificant. This has been observed that serum PCT levels were significantly higher in VAP patients who did not survive when compared to survivors with VAP \[[@CR19]\]. In pulmonary injury and pulmonary infection cases, the circulating PCT level and other precursors of calcitonin rise promptly, i.e., plausibly explained by release of sepsis-associated cytokines from pulmonary neuroendocrine cells of the bronchial epithelium and/or mononuclear cells \[[@CR20], [@CR21]\]. Approximately 23% among the studied patients had sepsis/bacteremia (2nd-day PCT level ≥ 1.15 ng/ml) at any point of hospital or ICU stay; out of them just 8% died primarily from it. This is in contrast with other studies where lethal outcome incidence reported to be quite significant \[[@CR6], [@CR22]\]. Jensen et al. \[[@CR23]\] demonstrated that mortality was significantly higher when PCT level exceeded 1.0 ng/mL on 2nd day, which was nearly in consonance with our results. The low incidence of sepsis and resulted mortality in our study may be justified on the basis of standard hygienic patient care on 1:1 (patient: nurse) ratio, point of care diagnostic and measurement tools, and hospital protocol including empirical broad spectrum antibiotics in all moderate to severe TBI patients.

In TBI patients, we observed initial PCT concentration on admission with a cutoff value of 5.5 ng/ml had a sensitivity and specificity of 75% approximately (with AUC 0.78) for primary mortality. Patients status post-intestinal and cardiothoracic surgery have been found to have a cutoff PCT level of 1.5--2 ng/ml as a marker of poor outcome \[[@CR24]--[@CR26]\]. Other factors that may lead to rise in PCT levels are post-major surgery, cardiogenic shock, medications, severe burns, and coexisting cancer \[[@CR25], [@CR27]\]. Moreover, any condition that decreases the blood oxygen level, irrespective of cause, can cause an elevated PCT even without infection (e.g., asthma, pneumonia, and cardiac arrest). The etiopathogenesis of the PCT rise after trauma is indicated to be multifactorial. Experimental studies have demonstrated that apart from bacterial endotoxins, many cytological factors like cellular-level interactions, their time-dependent activation, and response when pre-exposed to proinflammatory stimuli (TNF alpha, IL-2, IL-6) also contribute to its elevation \[[@CR20], [@CR28]\]. Polytrauma and postoperative patients may also show a PCT-level rise, suggestive of inflammation, during the post-traumatic or early postoperative period independently \[[@CR16], [@CR17], [@CR24]\]. Understanding this at a cytological level, quantitative PCT levels are produced by only adherent monocytes than the circulating monocytes since the adhesion receptors and molecules are also expressed in traumatized tissue.

However, with the given sensitivity/specificity this is uncertain to validate possible utility of PCT in TBI to predict early in-hospital mortality and this deserves to have further more trials on it. Further, extrapolating the results of this study may help in utilizing life-saving resources in severe TBI patients effectively in resource-limited developing areas/countries. The major limitations of this study were: limited data on diversity of associated injuries in polytrauma patients, assessment of outcomes mainly in terms of mortality (GOS-1), limited serial PCT sample collection after admission (on days 2 and 5), and limited logistic support on ICP monitoring devices through the study period.

Conclusion {#Sec7}
==========

Our findings do not fully support given hypothesis as PCT does not predict outcome in TBI patients as accurately as the physical or clinical examination. The predicted relationship between PCT levels and outcome was not established, and that these results do not support the prognostic utility of PCT biomarker for outcome assessment in TBI patients with or without extracranial injuries.
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